Uveal melanoma as a target for immune-therapy.
Uveal melanoma (UM) is a rare disease that can be deadly in spite of adequate local treatment. Systemic therapy with chemotherapy is usually ineffective and new-targeted therapies have not improved results considerably. The eye creates an immunosuppressive environment in order to protect eyesight. UM cells use similar processes to escape immune surveillance. Regarding innate immunity the production of macrophage inhibiting factor (MIF) and TGF-β, added to MHC class I upregulation, inhibits the action of natural killer (NK) cells. UM cells produce cytokines such as IL-6 and IL-10 that favor macrophage differentiation to the M2 subtype, which promote tumor growth instead of an effective immune response. UM cells also impair the adaptive immune response through production of indoleamine 2,3-dioxygenase (IDO), overexpression of programmed death ligand-1 (PD-L1), alteration of FasL expression, and resistance to perforin. This biological background suggests that immunotherapy could be effective in fighting UM. A Phase II clinical trial with Ipilimumab has shown promising results with mean Overall Survival rate of ten months, and close to 50% of the patients alive at one year. Clinical trials with anti-PD1 antibodies in monotherapy and in combination with anti-CTLA4 are currently recruiting patients worldwide.
Department of Medical Oncology, Genitourinary, Melanoma and Sarcoma Unit, Institut Català d'Oncologia, Barcelona, Spain.
Marc
M
Oliva
Department of Medical Oncology, Genitourinary, Melanoma and Sarcoma Unit, Institut Català d'Oncologia, Barcelona, Spain.
Antonio J
AJ
Rullan
Department of Medical Oncology, Genitourinary, Melanoma and Sarcoma Unit, Institut Català d'Oncologia, Barcelona, Spain.
Josep M
JM
Piulats
Uveal melanoma (UM); immune-system; immune-therapy